74232-79-4Relevant academic research and scientific papers
Compounds and Their Use in Treating Cancer
-
, (2019/07/10)
The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.
De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1
Ding, Xiao,Li, Yan,Lv, Li,Zhou, Mi,Han, Li,Zhang, Zhengxi,Ba, Qian,Li, Jingquan,Wang, Hui,Liu, Hong,Wang, Renxiao
, p. 1986 - 2014 (2014/01/06)
Considerable efforts have been made to the development of small-molecule inhibitors of antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins (such as Bcl-2, Bcl-xL, and Mcl-1) as a new class of anticancer therapies. Unlike general inhibitors
4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors
-
Example 21, (2010/02/05)
Heterocyclic compounds of the formula: ???whereinR1 is carboxy or esterified carboxy,R2 is phenyl or (C1-C6)alkylphenyl,R3 is phenyl or (C1-C6)alkylphenyl,R4 is hydrog
4,5-diaryl oxazole derivatives
-
, (2008/06/13)
This invention relates to new heterocyclic compounds, compositions, process of making and method of use thereof for inhibition of platelet aggregation, vasodilation, antihypertensive activity and prostaglandin I2 agonist.
